 Nanette Santoro
Concepts (906)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Menopause | 87 | 2023 | 266 | 18.090 |
Why?
| | Infertility, Female | 44 | 2023 | 94 | 9.040 |
Why?
| | Women's Health | 41 | 2023 | 273 | 6.750 |
Why?
| | Hot Flashes | 31 | 2023 | 72 | 6.680 |
Why?
| | Estrogen Replacement Therapy | 29 | 2023 | 117 | 6.350 |
Why?
| | Follicle Stimulating Hormone | 61 | 2022 | 216 | 6.180 |
Why?
| | Perimenopause | 24 | 2022 | 59 | 5.910 |
Why?
| | Luteinizing Hormone | 54 | 2022 | 173 | 5.530 |
Why?
| | Menstrual Cycle | 33 | 2023 | 113 | 5.420 |
Why?
| | Polycystic Ovary Syndrome | 33 | 2022 | 156 | 5.380 |
Why?
| | Estradiol | 56 | 2024 | 472 | 5.370 |
Why?
| | Postmenopause | 33 | 2020 | 305 | 4.320 |
Why?
| | Anti-Mullerian Hormone | 16 | 2023 | 51 | 4.250 |
Why?
| | Ovary | 23 | 2024 | 205 | 3.700 |
Why?
| | Endocrinology | 7 | 2023 | 68 | 3.540 |
Why?
| | Estrogens | 22 | 2024 | 327 | 3.440 |
Why?
| | Infertility | 11 | 2023 | 45 | 3.230 |
Why?
| | Progesterone | 37 | 2023 | 241 | 3.140 |
Why?
| | Female | 326 | 2024 | 61140 | 3.130 |
Why?
| | Ovulation Induction | 29 | 2022 | 50 | 2.940 |
Why?
| | Primary Ovarian Insufficiency | 13 | 2021 | 30 | 2.930 |
Why?
| | Fertilization in Vitro | 17 | 2022 | 73 | 2.850 |
Why?
| | Androgens | 15 | 2021 | 167 | 2.790 |
Why?
| | Luteal Phase | 16 | 2020 | 44 | 2.690 |
Why?
| | Obesity | 29 | 2022 | 2715 | 2.630 |
Why?
| | Hormones | 12 | 2021 | 135 | 2.610 |
Why?
| | Metabolic Syndrome | 14 | 2021 | 392 | 2.580 |
Why?
| | Reproduction | 8 | 2022 | 189 | 2.430 |
Why?
| | Humans | 344 | 2024 | 118053 | 2.430 |
Why?
| | Fertility | 14 | 2022 | 134 | 2.280 |
Why?
| | Reproductive Medicine | 6 | 2023 | 13 | 2.210 |
Why?
| | Aging | 26 | 2024 | 1672 | 2.180 |
Why?
| | Adult | 180 | 2024 | 31227 | 2.060 |
Why?
| | Endometrium | 15 | 2020 | 61 | 2.050 |
Why?
| | Ovulation | 14 | 2018 | 41 | 1.990 |
Why?
| | Testosterone | 24 | 2021 | 350 | 1.980 |
Why?
| | Live Birth | 20 | 2022 | 47 | 1.960 |
Why?
| | Fertility Agents, Female | 14 | 2022 | 19 | 1.940 |
Why?
| | Ovarian Follicle | 10 | 2024 | 61 | 1.940 |
Why?
| | Menopause, Premature | 4 | 2021 | 8 | 1.930 |
Why?
| | Gonadal Steroid Hormones | 12 | 2024 | 122 | 1.850 |
Why?
| | Estrogens, Conjugated (USP) | 12 | 2023 | 34 | 1.750 |
Why?
| | Hormone Replacement Therapy | 9 | 2022 | 80 | 1.730 |
Why?
| | Sexual Dysfunction, Physiological | 9 | 2018 | 60 | 1.720 |
Why?
| | Quality of Life | 17 | 2023 | 2360 | 1.650 |
Why?
| | Infertility, Male | 11 | 2022 | 61 | 1.640 |
Why?
| | Depression | 12 | 2019 | 1134 | 1.640 |
Why?
| | Cardiovascular Diseases | 21 | 2024 | 1795 | 1.640 |
Why?
| | Carotid Intima-Media Thickness | 10 | 2021 | 68 | 1.550 |
Why?
| | Middle Aged | 116 | 2024 | 27431 | 1.480 |
Why?
| | Amenorrhea | 12 | 2017 | 28 | 1.450 |
Why?
| | Pregnanediol | 10 | 2020 | 12 | 1.440 |
Why?
| | Pregnancy | 63 | 2024 | 5667 | 1.440 |
Why?
| | Vagina | 3 | 2020 | 150 | 1.440 |
Why?
| | Gonadotropin-Releasing Hormone | 16 | 2022 | 193 | 1.430 |
Why?
| | Biomarkers | 31 | 2022 | 3564 | 1.410 |
Why?
| | Body Mass Index | 34 | 2022 | 2074 | 1.410 |
Why?
| | Vasomotor System | 8 | 2021 | 47 | 1.380 |
Why?
| | Pregnancy Rate | 20 | 2022 | 55 | 1.370 |
Why?
| | Vaginal Diseases | 3 | 2020 | 17 | 1.360 |
Why?
| | Estrone | 11 | 2024 | 35 | 1.350 |
Why?
| | Endocrinologists | 3 | 2023 | 12 | 1.350 |
Why?
| | Hypothalamus | 10 | 2014 | 155 | 1.340 |
Why?
| | Premenopause | 13 | 2022 | 107 | 1.300 |
Why?
| | Hormone Antagonists | 2 | 2021 | 40 | 1.280 |
Why?
| | Double-Blind Method | 29 | 2023 | 1679 | 1.270 |
Why?
| | Inhibins | 8 | 2018 | 46 | 1.260 |
Why?
| | Atherosclerosis | 6 | 2024 | 344 | 1.240 |
Why?
| | Gynecology | 2 | 2021 | 184 | 1.200 |
Why?
| | Receptors, Neurokinin-3 | 3 | 2023 | 6 | 1.190 |
Why?
| | Endometriosis | 4 | 2022 | 42 | 1.180 |
Why?
| | Anovulation | 7 | 2015 | 8 | 1.160 |
Why?
| | Hyperlipidemias | 5 | 2022 | 127 | 1.150 |
Why?
| | Uterus | 4 | 2019 | 197 | 1.120 |
Why?
| | Prospective Studies | 42 | 2024 | 6443 | 1.070 |
Why?
| | Sleep Wake Disorders | 6 | 2021 | 239 | 1.060 |
Why?
| | Clomiphene | 9 | 2021 | 15 | 1.060 |
Why?
| | Hyperinsulinism | 3 | 2022 | 107 | 1.060 |
Why?
| | Patient Selection | 7 | 2021 | 669 | 1.050 |
Why?
| | Aromatase Inhibitors | 3 | 2020 | 50 | 1.040 |
Why?
| | Insulin | 11 | 2022 | 2153 | 1.030 |
Why?
| | Embryo Transfer | 9 | 2022 | 28 | 1.030 |
Why?
| | Randomized Controlled Trials as Topic | 19 | 2023 | 1237 | 1.020 |
Why?
| | Mental Health | 2 | 2022 | 565 | 1.000 |
Why?
| | Sex Hormone-Binding Globulin | 14 | 2020 | 49 | 0.980 |
Why?
| | HIV Infections | 17 | 2024 | 2448 | 0.970 |
Why?
| | Follicle Stimulating Hormone, Human | 3 | 2022 | 11 | 0.960 |
Why?
| | Biomedical Research | 4 | 2023 | 601 | 0.960 |
Why?
| | Salpingo-oophorectomy | 1 | 2024 | 12 | 0.960 |
Why?
| | Life Cycle Stages | 1 | 2023 | 30 | 0.950 |
Why?
| | Cryopreservation | 4 | 2022 | 99 | 0.930 |
Why?
| | Longitudinal Studies | 25 | 2020 | 2487 | 0.920 |
Why?
| | United States | 49 | 2023 | 12477 | 0.920 |
Why?
| | Menarche | 2 | 2017 | 51 | 0.920 |
Why?
| | Gonadotropins | 5 | 2020 | 37 | 0.900 |
Why?
| | Aromatase | 3 | 2014 | 31 | 0.890 |
Why?
| | Progestins | 4 | 2017 | 77 | 0.870 |
Why?
| | Ovarian Reserve | 3 | 2020 | 13 | 0.860 |
Why?
| | Drug Compounding | 3 | 2021 | 90 | 0.860 |
Why?
| | Hypothalamo-Hypophyseal System | 5 | 2017 | 194 | 0.860 |
Why?
| | Sexual Health | 1 | 2023 | 44 | 0.860 |
Why?
| | Irritable Mood | 3 | 2018 | 51 | 0.850 |
Why?
| | Lipids | 7 | 2023 | 591 | 0.850 |
Why?
| | Health Knowledge, Attitudes, Practice | 4 | 2021 | 1179 | 0.830 |
Why?
| | Pituitary Gland | 6 | 2021 | 163 | 0.830 |
Why?
| | Treatment Outcome | 35 | 2023 | 9310 | 0.820 |
Why?
| | Sleep Initiation and Maintenance Disorders | 4 | 2018 | 118 | 0.810 |
Why?
| | Corpus Luteum | 7 | 2017 | 21 | 0.800 |
Why?
| | Administration, Cutaneous | 12 | 2023 | 118 | 0.790 |
Why?
| | Hydrocortisone | 4 | 2022 | 272 | 0.790 |
Why?
| | Soybean Oil | 1 | 2021 | 12 | 0.790 |
Why?
| | Age Factors | 22 | 2023 | 2989 | 0.790 |
Why?
| | Fetal Research | 1 | 2021 | 3 | 0.790 |
Why?
| | Embryo, Mammalian | 1 | 2022 | 219 | 0.790 |
Why?
| | Research Subjects | 1 | 2021 | 40 | 0.790 |
Why?
| | Federal Government | 1 | 2021 | 26 | 0.780 |
Why?
| | Bicycling | 1 | 2021 | 77 | 0.770 |
Why?
| | Hand Strength | 1 | 2021 | 99 | 0.770 |
Why?
| | Cross-Sectional Studies | 30 | 2022 | 4518 | 0.750 |
Why?
| | Symptom Assessment | 2 | 2021 | 122 | 0.740 |
Why?
| | Fatty Acids, Nonesterified | 1 | 2021 | 162 | 0.740 |
Why?
| | Sleep | 9 | 2021 | 652 | 0.740 |
Why?
| | Adolescent | 47 | 2021 | 18339 | 0.740 |
Why?
| | Reproductive Health | 3 | 2023 | 68 | 0.730 |
Why?
| | Longevity | 1 | 2021 | 150 | 0.720 |
Why?
| | Ultrasonography | 6 | 2018 | 714 | 0.710 |
Why?
| | Premature Birth | 3 | 2022 | 284 | 0.710 |
Why?
| | Obstetrics | 1 | 2021 | 162 | 0.700 |
Why?
| | Phospholipids | 1 | 2021 | 207 | 0.700 |
Why?
| | Young Adult | 32 | 2022 | 10705 | 0.690 |
Why?
| | Risk Factors | 45 | 2022 | 8949 | 0.690 |
Why?
| | Hypogonadism | 8 | 2015 | 77 | 0.690 |
Why?
| | Practice Guidelines as Topic | 3 | 2016 | 1434 | 0.680 |
Why?
| | Spatial Memory | 1 | 2019 | 17 | 0.670 |
Why?
| | Sexuality | 1 | 2018 | 18 | 0.670 |
Why?
| | Hysterosalpingography | 1 | 2018 | 6 | 0.670 |
Why?
| | Cohort Studies | 28 | 2023 | 5072 | 0.660 |
Why?
| | Ovarian Hyperstimulation Syndrome | 3 | 2008 | 6 | 0.650 |
Why?
| | Hypothalamic Diseases | 3 | 2017 | 18 | 0.650 |
Why?
| | Life Style | 10 | 2024 | 431 | 0.630 |
Why?
| | Insemination, Artificial | 5 | 2022 | 12 | 0.610 |
Why?
| | Heterocyclic Compounds, 2-Ring | 3 | 2023 | 5 | 0.610 |
Why?
| | Substance-Related Disorders | 6 | 2009 | 966 | 0.590 |
Why?
| | Health Surveys | 5 | 2011 | 453 | 0.580 |
Why?
| | Hypopituitarism | 2 | 2014 | 15 | 0.570 |
Why?
| | Fetus | 1 | 2021 | 690 | 0.570 |
Why?
| | Circadian Rhythm | 3 | 2017 | 395 | 0.560 |
Why?
| | Hysterectomy | 5 | 2023 | 117 | 0.560 |
Why?
| | Pregnancy Trimester, First | 2 | 2019 | 126 | 0.560 |
Why?
| | Overweight | 5 | 2014 | 492 | 0.550 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2016 | 26 | 0.550 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2011 | 267 | 0.550 |
Why?
| | Chorionic Gonadotropin | 9 | 2021 | 80 | 0.550 |
Why?
| | Cumulus Cells | 2 | 2015 | 6 | 0.550 |
Why?
| | Cognition | 10 | 2022 | 1023 | 0.550 |
Why?
| | Levonorgestrel | 1 | 2015 | 32 | 0.540 |
Why?
| | Surveys and Questionnaires | 20 | 2022 | 4682 | 0.540 |
Why?
| | Sweating | 4 | 2018 | 24 | 0.530 |
Why?
| | Adiposity | 4 | 2020 | 508 | 0.530 |
Why?
| | Uterine Hemorrhage | 3 | 2021 | 36 | 0.530 |
Why?
| | Insemination, Artificial, Heterologous | 1 | 2015 | 2 | 0.520 |
Why?
| | Tandem Mass Spectrometry | 2 | 2015 | 418 | 0.520 |
Why?
| | Azoospermia | 1 | 2015 | 6 | 0.520 |
Why?
| | Abortion, Spontaneous | 6 | 2021 | 94 | 0.510 |
Why?
| | Anxiety | 4 | 2018 | 844 | 0.500 |
Why?
| | Bone Density | 7 | 2011 | 447 | 0.500 |
Why?
| | Pulsatile Flow | 3 | 2011 | 54 | 0.490 |
Why?
| | Blood Chemical Analysis | 1 | 2015 | 94 | 0.490 |
Why?
| | Vulvodynia | 1 | 2014 | 2 | 0.490 |
Why?
| | Granulosa Cells | 4 | 2021 | 30 | 0.490 |
Why?
| | Nitriles | 5 | 2015 | 155 | 0.490 |
Why?
| | Body Composition | 9 | 2024 | 644 | 0.480 |
Why?
| | Cross-Over Studies | 4 | 2022 | 448 | 0.470 |
Why?
| | Triazoles | 5 | 2015 | 128 | 0.470 |
Why?
| | Indoles | 1 | 2016 | 310 | 0.470 |
Why?
| | Blood Proteins | 1 | 2015 | 240 | 0.460 |
Why?
| | Pregnancy Outcome | 9 | 2021 | 350 | 0.460 |
Why?
| | Osteoporosis | 1 | 2016 | 226 | 0.450 |
Why?
| | Pregnancy, Multiple | 4 | 2015 | 19 | 0.450 |
Why?
| | Solubility | 2 | 2023 | 234 | 0.440 |
Why?
| | Time Factors | 18 | 2021 | 6362 | 0.430 |
Why?
| | Insulin Resistance | 9 | 2023 | 1167 | 0.430 |
Why?
| | Male | 64 | 2023 | 57370 | 0.430 |
Why?
| | Stress, Psychological | 8 | 2018 | 967 | 0.430 |
Why?
| | Parity | 2 | 2011 | 100 | 0.430 |
Why?
| | Complementary Therapies | 3 | 2022 | 71 | 0.430 |
Why?
| | Insemination, Artificial, Homologous | 3 | 2021 | 3 | 0.420 |
Why?
| | Follicular Phase | 12 | 2014 | 41 | 0.420 |
Why?
| | Cell Cycle | 1 | 2015 | 546 | 0.420 |
Why?
| | Prolactin | 4 | 2022 | 96 | 0.410 |
Why?
| | Plaque, Atherosclerotic | 2 | 2024 | 40 | 0.410 |
Why?
| | Prevalence | 13 | 2019 | 2321 | 0.410 |
Why?
| | Intracranial Thrombosis | 1 | 2011 | 17 | 0.400 |
Why?
| | Follow-Up Studies | 16 | 2023 | 4571 | 0.400 |
Why?
| | Menstruation | 9 | 2012 | 36 | 0.400 |
Why?
| | Fallopian Tubes | 3 | 2018 | 28 | 0.390 |
Why?
| | Endocrine System | 1 | 2011 | 22 | 0.390 |
Why?
| | Thyrotropin | 3 | 2022 | 104 | 0.390 |
Why?
| | Antiretroviral Therapy, Highly Active | 5 | 2008 | 258 | 0.390 |
Why?
| | Weight Gain | 5 | 2020 | 486 | 0.390 |
Why?
| | Pregnancy, Ectopic | 3 | 2021 | 53 | 0.390 |
Why?
| | Exercise | 3 | 2022 | 1647 | 0.380 |
Why?
| | Uterine Diseases | 2 | 2007 | 14 | 0.380 |
Why?
| | Thiadiazoles | 2 | 2020 | 21 | 0.370 |
Why?
| | Methotrexate | 4 | 2021 | 227 | 0.370 |
Why?
| | Coronary Artery Disease | 4 | 2019 | 648 | 0.370 |
Why?
| | Abortifacient Agents, Nonsteroidal | 2 | 2021 | 19 | 0.370 |
Why?
| | Logistic Models | 14 | 2015 | 1894 | 0.360 |
Why?
| | Reproductive Techniques, Assisted | 3 | 2021 | 33 | 0.360 |
Why?
| | Activins | 3 | 2005 | 26 | 0.360 |
Why?
| | Watchful Waiting | 2 | 2021 | 55 | 0.360 |
Why?
| | Prognosis | 14 | 2020 | 3420 | 0.360 |
Why?
| | Regression Analysis | 7 | 2020 | 984 | 0.350 |
Why?
| | Oocyte Donation | 1 | 2009 | 5 | 0.350 |
Why?
| | Odds Ratio | 14 | 2015 | 992 | 0.350 |
Why?
| | Multicenter Studies as Topic | 8 | 2022 | 251 | 0.350 |
Why?
| | Vulva | 1 | 2009 | 24 | 0.350 |
Why?
| | Trinucleotide Repeats | 1 | 2009 | 24 | 0.340 |
Why?
| | Hyperandrogenism | 4 | 2017 | 14 | 0.340 |
Why?
| | Administration, Oral | 8 | 2020 | 751 | 0.340 |
Why?
| | Fertility Agents | 2 | 2020 | 2 | 0.340 |
Why?
| | Luteal Cells | 1 | 2008 | 2 | 0.340 |
Why?
| | Signal Transduction | 3 | 2021 | 4676 | 0.340 |
Why?
| | Semen | 4 | 2022 | 18 | 0.340 |
Why?
| | Multivariate Analysis | 13 | 2015 | 1468 | 0.330 |
Why?
| | Breast Neoplasms | 4 | 2022 | 1945 | 0.330 |
Why?
| | Pituitary Hormone-Releasing Hormones | 6 | 1989 | 10 | 0.330 |
Why?
| | Fragile X Mental Retardation Protein | 1 | 2009 | 65 | 0.330 |
Why?
| | Ovariectomy | 3 | 2023 | 124 | 0.330 |
Why?
| | Adaptation, Psychological | 3 | 2018 | 545 | 0.320 |
Why?
| | Mentors | 1 | 2010 | 166 | 0.320 |
Why?
| | Administration, Intravaginal | 2 | 2020 | 21 | 0.320 |
Why?
| | Carotid Artery Diseases | 2 | 2020 | 58 | 0.320 |
Why?
| | Evidence-Based Medicine | 5 | 2017 | 689 | 0.320 |
Why?
| | Bone Remodeling | 2 | 2008 | 64 | 0.320 |
Why?
| | Vitamin D Deficiency | 2 | 2021 | 161 | 0.320 |
Why?
| | Mood Disorders | 3 | 2015 | 119 | 0.320 |
Why?
| | Bone Diseases, Metabolic | 1 | 2008 | 60 | 0.320 |
Why?
| | Oocyte Retrieval | 3 | 2015 | 12 | 0.310 |
Why?
| | Aged | 21 | 2023 | 19555 | 0.310 |
Why?
| | Polyps | 1 | 2007 | 13 | 0.310 |
Why?
| | Leiomyoma | 2 | 2019 | 45 | 0.310 |
Why?
| | Metformin | 3 | 2012 | 293 | 0.310 |
Why?
| | Incidence | 8 | 2020 | 2413 | 0.310 |
Why?
| | Pericardium | 3 | 2019 | 50 | 0.300 |
Why?
| | Vitamin D | 3 | 2021 | 352 | 0.300 |
Why?
| | Virilism | 1 | 2007 | 5 | 0.300 |
Why?
| | Non-alcoholic Fatty Liver Disease | 2 | 2023 | 277 | 0.290 |
Why?
| | Lactation | 1 | 2008 | 156 | 0.290 |
Why?
| | Dehydroepiandrosterone Sulfate | 6 | 2011 | 43 | 0.290 |
Why?
| | Antioxidants | 2 | 2021 | 562 | 0.290 |
Why?
| | Reproductive Techniques | 3 | 2001 | 6 | 0.290 |
Why?
| | Fertilization | 3 | 2022 | 43 | 0.290 |
Why?
| | Pituitary-Adrenal System | 3 | 2017 | 158 | 0.290 |
Why?
| | Affect | 3 | 2018 | 238 | 0.280 |
Why?
| | Metabolome | 1 | 2009 | 288 | 0.280 |
Why?
| | Pilot Projects | 5 | 2020 | 1405 | 0.280 |
Why?
| | Weight Loss | 5 | 2024 | 652 | 0.280 |
Why?
| | Cytokines | 3 | 2021 | 1879 | 0.280 |
Why?
| | Specimen Handling | 3 | 2018 | 161 | 0.280 |
Why?
| | Risk Assessment | 11 | 2022 | 3041 | 0.280 |
Why?
| | Attitude to Health | 3 | 2009 | 410 | 0.280 |
Why?
| | Inflammation | 3 | 2022 | 2545 | 0.270 |
Why?
| | Bariatric Surgery | 1 | 2008 | 166 | 0.270 |
Why?
| | New York City | 6 | 2010 | 74 | 0.270 |
Why?
| | Cholesterol, LDL | 2 | 2010 | 316 | 0.270 |
Why?
| | Leuprolide | 4 | 1998 | 20 | 0.270 |
Why?
| | Case-Control Studies | 7 | 2020 | 3142 | 0.260 |
Why?
| | Contraceptive Agents, Female | 2 | 2016 | 65 | 0.260 |
Why?
| | Atrophy | 2 | 2020 | 164 | 0.260 |
Why?
| | Oxidative Stress | 2 | 2021 | 1167 | 0.250 |
Why?
| | Dehydroepiandrosterone | 5 | 2016 | 51 | 0.250 |
Why?
| | Follistatin | 1 | 2004 | 12 | 0.250 |
Why?
| | Age of Onset | 3 | 2017 | 463 | 0.250 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2021 | 3357 | 0.250 |
Why?
| | Socioeconomic Factors | 7 | 2013 | 1121 | 0.250 |
Why?
| | C-Reactive Protein | 4 | 2022 | 364 | 0.250 |
Why?
| | Biology | 2 | 2023 | 80 | 0.250 |
Why?
| | Recovery of Function | 1 | 2008 | 603 | 0.250 |
Why?
| | Academic Medical Centers | 4 | 2021 | 422 | 0.240 |
Why?
| | Vascular Calcification | 2 | 2019 | 123 | 0.240 |
Why?
| | Skin Aging | 2 | 2016 | 20 | 0.240 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 960 | 0.240 |
Why?
| | Adipose Tissue | 3 | 2019 | 595 | 0.230 |
Why?
| | Insulin-Like Growth Factor I | 4 | 2022 | 285 | 0.230 |
Why?
| | Oligomenorrhea | 2 | 2014 | 6 | 0.230 |
Why?
| | Endometrial Hyperplasia | 1 | 2023 | 16 | 0.230 |
Why?
| | Fractures, Bone | 2 | 2008 | 376 | 0.230 |
Why?
| | Carotid Stenosis | 1 | 2024 | 75 | 0.230 |
Why?
| | Bone Resorption | 2 | 2015 | 80 | 0.230 |
Why?
| | Drug Therapy, Combination | 5 | 2018 | 963 | 0.230 |
Why?
| | National Institute of Child Health and Human Development (U.S.) | 2 | 2023 | 8 | 0.220 |
Why?
| | Dyspareunia | 2 | 2016 | 8 | 0.220 |
Why?
| | Child | 22 | 2023 | 19026 | 0.220 |
Why?
| | Reference Values | 8 | 2020 | 764 | 0.220 |
Why?
| | Cell Cycle Proteins | 1 | 2007 | 563 | 0.220 |
Why?
| | Interleukin-6 | 2 | 2022 | 685 | 0.220 |
Why?
| | Dilatation and Curettage | 2 | 2021 | 10 | 0.220 |
Why?
| | Diabetes Mellitus | 3 | 2023 | 939 | 0.220 |
Why?
| | Anti-HIV Agents | 2 | 2005 | 661 | 0.220 |
Why?
| | Referral and Consultation | 3 | 2016 | 640 | 0.220 |
Why?
| | Asymptomatic Diseases | 3 | 2018 | 81 | 0.220 |
Why?
| | Reimbursement Mechanisms | 2 | 2001 | 79 | 0.210 |
Why?
| | Animals | 14 | 2023 | 33101 | 0.210 |
Why?
| | Cuba | 3 | 2010 | 11 | 0.210 |
Why?
| | Human Growth Hormone | 1 | 2022 | 37 | 0.210 |
Why?
| | Goals | 1 | 2023 | 164 | 0.210 |
Why?
| | Central America | 3 | 2010 | 27 | 0.210 |
Why?
| | Simvastatin | 1 | 2002 | 65 | 0.210 |
Why?
| | Puerto Rico | 3 | 2010 | 54 | 0.210 |
Why?
| | South America | 3 | 2010 | 56 | 0.210 |
Why?
| | Washington | 1 | 2022 | 141 | 0.210 |
Why?
| | Germ Cells | 1 | 2022 | 64 | 0.200 |
Why?
| | Smoking | 6 | 2015 | 1469 | 0.200 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2022 | 79 | 0.200 |
Why?
| | Ankle Brachial Index | 1 | 2021 | 30 | 0.200 |
Why?
| | Semen Analysis | 4 | 2022 | 10 | 0.200 |
Why?
| | Health Behavior | 1 | 2007 | 714 | 0.200 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 143 | 0.200 |
Why?
| | Urologic Surgical Procedures, Male | 2 | 2011 | 27 | 0.200 |
Why?
| | Transcription Factor CHOP | 1 | 2021 | 28 | 0.200 |
Why?
| | Emulsions | 1 | 2021 | 44 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 2 | 2017 | 3160 | 0.190 |
Why?
| | Fat Emulsions, Intravenous | 1 | 2021 | 31 | 0.190 |
Why?
| | Sexual Behavior | 3 | 2016 | 435 | 0.190 |
Why?
| | Pulse Wave Analysis | 1 | 2021 | 216 | 0.190 |
Why?
| | Biomarkers, Tumor | 1 | 2007 | 1051 | 0.190 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2023 | 246 | 0.190 |
Why?
| | Linear Models | 7 | 2019 | 814 | 0.190 |
Why?
| | Thinness | 1 | 2021 | 91 | 0.190 |
Why?
| | Cell Proliferation | 2 | 2009 | 2254 | 0.190 |
Why?
| | Genetic Fitness | 1 | 2021 | 55 | 0.190 |
Why?
| | Drug Combinations | 3 | 2016 | 292 | 0.190 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2021 | 96 | 0.190 |
Why?
| | Heat-Shock Proteins | 1 | 2021 | 127 | 0.190 |
Why?
| | Dominican Republic | 2 | 2010 | 19 | 0.190 |
Why?
| | Glucose Clamp Technique | 1 | 2021 | 194 | 0.190 |
Why?
| | Obesity, Abdominal | 2 | 2022 | 39 | 0.180 |
Why?
| | Spermatozoa | 3 | 2022 | 91 | 0.180 |
Why?
| | Vitamins | 1 | 2021 | 157 | 0.180 |
Why?
| | RNA, Messenger | 6 | 2011 | 2656 | 0.180 |
Why?
| | Coitus | 2 | 2022 | 28 | 0.180 |
Why?
| | Choice Behavior | 1 | 2021 | 160 | 0.180 |
Why?
| | Lipoproteins, HDL | 3 | 2015 | 82 | 0.180 |
Why?
| | Electronics | 1 | 2000 | 71 | 0.180 |
Why?
| | Ethics, Medical | 1 | 2000 | 71 | 0.180 |
Why?
| | Growth Hormone | 2 | 2022 | 107 | 0.180 |
Why?
| | Osteoporosis, Postmenopausal | 2 | 2011 | 38 | 0.180 |
Why?
| | Puberty | 2 | 2019 | 143 | 0.180 |
Why?
| | Down-Regulation | 5 | 2019 | 623 | 0.180 |
Why?
| | Fibroblast Growth Factors | 1 | 2021 | 174 | 0.170 |
Why?
| | Gonadotropins, Pituitary | 4 | 2011 | 22 | 0.170 |
Why?
| | Leptin | 3 | 2022 | 228 | 0.170 |
Why?
| | Erectile Dysfunction | 1 | 2019 | 37 | 0.170 |
Why?
| | Surgeons | 1 | 2023 | 242 | 0.170 |
Why?
| | Cell Nucleolus | 2 | 2010 | 17 | 0.170 |
Why?
| | Gene Expression | 3 | 2021 | 1480 | 0.170 |
Why?
| | Pre-Eclampsia | 2 | 2018 | 183 | 0.170 |
Why?
| | Acculturation | 2 | 2010 | 51 | 0.170 |
Why?
| | Spermatogenesis | 1 | 2019 | 53 | 0.170 |
Why?
| | Adiponectin | 3 | 2022 | 224 | 0.170 |
Why?
| | Decidua | 1 | 2019 | 27 | 0.170 |
Why?
| | Insulin-Like Growth Factor Binding Protein 1 | 1 | 2019 | 24 | 0.170 |
Why?
| | Sperm Count | 4 | 2022 | 16 | 0.170 |
Why?
| | Gene Expression Regulation, Developmental | 3 | 2015 | 810 | 0.170 |
Why?
| | Menstruation Disturbances | 1 | 2018 | 12 | 0.170 |
Why?
| | Carotid Arteries | 1 | 2020 | 184 | 0.160 |
Why?
| | Patient Reported Outcome Measures | 1 | 2020 | 251 | 0.160 |
Why?
| | Allostasis | 1 | 2018 | 14 | 0.160 |
Why?
| | Ovarian Diseases | 3 | 1993 | 12 | 0.160 |
Why?
| | Ethics Committees, Research | 1 | 2018 | 40 | 0.160 |
Why?
| | Waist Circumference | 5 | 2022 | 130 | 0.160 |
Why?
| | Adrenal Glands | 1 | 1998 | 72 | 0.160 |
Why?
| | Decision Support Techniques | 1 | 2022 | 365 | 0.160 |
Why?
| | Genitalia | 1 | 2018 | 27 | 0.160 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2002 | 387 | 0.160 |
Why?
| | Precision Medicine | 1 | 2022 | 354 | 0.160 |
Why?
| | Child Behavior | 1 | 2020 | 213 | 0.160 |
Why?
| | Periodicity | 8 | 2016 | 56 | 0.160 |
Why?
| | Placebos | 2 | 2015 | 200 | 0.150 |
Why?
| | Keratin-18 | 1 | 2017 | 11 | 0.150 |
Why?
| | Religion | 1 | 2018 | 68 | 0.150 |
Why?
| | Clinical Protocols | 1 | 2018 | 234 | 0.150 |
Why?
| | Phytotherapy | 1 | 2017 | 69 | 0.150 |
Why?
| | Adult Survivors of Child Abuse | 1 | 2017 | 20 | 0.150 |
Why?
| | Brachial Artery | 1 | 2018 | 180 | 0.150 |
Why?
| | Comorbidity | 5 | 2014 | 1519 | 0.150 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2017 | 28 | 0.150 |
Why?
| | Oligonucleotide Array Sequence Analysis | 3 | 2015 | 762 | 0.150 |
Why?
| | Disease Progression | 4 | 2020 | 2475 | 0.150 |
Why?
| | Receptors, Leptin | 2 | 2013 | 26 | 0.140 |
Why?
| | Models, Biological | 5 | 2016 | 1698 | 0.140 |
Why?
| | Evidence-Based Practice | 1 | 2018 | 193 | 0.140 |
Why?
| | Regional Blood Flow | 1 | 2018 | 416 | 0.140 |
Why?
| | Feeding and Eating Disorders | 1 | 2018 | 125 | 0.140 |
Why?
| | Antidepressive Agents | 1 | 2018 | 191 | 0.140 |
Why?
| | Body Weight | 4 | 2015 | 923 | 0.140 |
Why?
| | Microbiota | 1 | 2024 | 656 | 0.140 |
Why?
| | Vaginal Creams, Foams, and Jellies | 1 | 2016 | 6 | 0.140 |
Why?
| | Orgasm | 1 | 2016 | 6 | 0.140 |
Why?
| | Uterine Neoplasms | 1 | 2017 | 76 | 0.140 |
Why?
| | Oxytocics | 1 | 2016 | 14 | 0.140 |
Why?
| | Heart | 1 | 2020 | 630 | 0.140 |
Why?
| | Consensus Development Conferences as Topic | 1 | 2016 | 31 | 0.140 |
Why?
| | Societies, Scientific | 1 | 2016 | 49 | 0.140 |
Why?
| | Endocrine System Diseases | 1 | 2016 | 32 | 0.140 |
Why?
| | Causality | 2 | 2014 | 109 | 0.140 |
Why?
| | Health Status | 3 | 2023 | 723 | 0.140 |
Why?
| | Fetal Growth Retardation | 2 | 2019 | 468 | 0.140 |
Why?
| | Infant | 15 | 2024 | 8256 | 0.140 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2009 | 1372 | 0.130 |
Why?
| | Fluoroimmunoassay | 2 | 1999 | 3 | 0.130 |
Why?
| | Child Development | 1 | 2020 | 404 | 0.130 |
Why?
| | Oxytocin | 1 | 2016 | 44 | 0.130 |
Why?
| | Gene Expression Profiling | 2 | 2015 | 1588 | 0.130 |
Why?
| | Chlamydia trachomatis | 1 | 2015 | 36 | 0.130 |
Why?
| | Confidence Intervals | 4 | 2011 | 324 | 0.130 |
Why?
| | Hirsutism | 2 | 2017 | 10 | 0.130 |
Why?
| | Observational Studies as Topic | 1 | 2016 | 88 | 0.130 |
Why?
| | Chromatography, Liquid | 2 | 2015 | 352 | 0.130 |
Why?
| | Intrauterine Devices, Medicated | 1 | 2015 | 25 | 0.130 |
Why?
| | Body Constitution | 3 | 2004 | 47 | 0.130 |
Why?
| | Societies, Medical | 3 | 2017 | 700 | 0.130 |
Why?
| | Genome-Wide Association Study | 1 | 2022 | 1308 | 0.130 |
Why?
| | Mobility Limitation | 1 | 2015 | 62 | 0.130 |
Why?
| | Infant, Newborn | 8 | 2022 | 5227 | 0.130 |
Why?
| | Patient Dropouts | 1 | 2015 | 66 | 0.130 |
Why?
| | Migraine Disorders | 1 | 2016 | 79 | 0.130 |
Why?
| | Vasodilation | 1 | 2018 | 456 | 0.130 |
Why?
| | Stress, Physiological | 1 | 2018 | 414 | 0.130 |
Why?
| | Drug Approval | 1 | 2015 | 77 | 0.130 |
Why?
| | Limit of Detection | 1 | 2015 | 55 | 0.130 |
Why?
| | Depressive Disorder, Major | 1 | 2018 | 301 | 0.130 |
Why?
| | Phosphoprotein Phosphatases | 1 | 2015 | 67 | 0.130 |
Why?
| | Chlamydia Infections | 1 | 2015 | 65 | 0.130 |
Why?
| | Antibodies, Bacterial | 1 | 2015 | 124 | 0.130 |
Why?
| | Air Pollution | 1 | 2017 | 198 | 0.130 |
Why?
| | Contraindications | 1 | 2014 | 86 | 0.120 |
Why?
| | Adaptation, Physiological | 1 | 2018 | 501 | 0.120 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 174 | 0.120 |
Why?
| | Survival Analysis | 4 | 2014 | 1261 | 0.120 |
Why?
| | Electronic Health Records | 1 | 2021 | 809 | 0.120 |
Why?
| | Diabetes, Gestational | 1 | 2018 | 284 | 0.120 |
Why?
| | Physical Fitness | 1 | 2015 | 179 | 0.120 |
Why?
| | Cellular Microenvironment | 1 | 2015 | 78 | 0.120 |
Why?
| | Predictive Value of Tests | 4 | 2016 | 1850 | 0.120 |
Why?
| | Immunoglobulin G | 2 | 2015 | 785 | 0.120 |
Why?
| | Laparoscopy | 1 | 2018 | 417 | 0.120 |
Why?
| | Arthritis, Psoriatic | 1 | 2014 | 16 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2021 | 538 | 0.120 |
Why?
| | Retrospective Studies | 11 | 2022 | 12921 | 0.120 |
Why?
| | Sperm Motility | 3 | 2022 | 28 | 0.120 |
Why?
| | Fatigue | 1 | 2015 | 293 | 0.120 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2015 | 333 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2015 | 6533 | 0.120 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2021 | 1159 | 0.120 |
Why?
| | Creatinine | 3 | 2022 | 491 | 0.120 |
Why?
| | Oocytes | 2 | 2011 | 185 | 0.120 |
Why?
| | Child, Preschool | 15 | 2020 | 9441 | 0.120 |
Why?
| | Bone Marrow Transplantation | 4 | 1999 | 244 | 0.120 |
Why?
| | Range of Motion, Articular | 1 | 2015 | 369 | 0.110 |
Why?
| | Cluster Analysis | 1 | 2015 | 478 | 0.110 |
Why?
| | Methadone | 2 | 2011 | 69 | 0.110 |
Why?
| | Muscle Strength | 1 | 2015 | 283 | 0.110 |
Why?
| | Liver | 3 | 2023 | 1802 | 0.110 |
Why?
| | Autoimmunity | 1 | 1999 | 831 | 0.110 |
Why?
| | Anxiety Disorders | 1 | 2015 | 310 | 0.110 |
Why?
| | Retinol-Binding Proteins, Plasma | 1 | 2012 | 5 | 0.110 |
Why?
| | Chi-Square Distribution | 4 | 2015 | 523 | 0.110 |
Why?
| | Rats | 3 | 2019 | 5329 | 0.110 |
Why?
| | Drug Administration Schedule | 2 | 2012 | 732 | 0.110 |
Why?
| | Epithelial Cells | 2 | 2009 | 949 | 0.110 |
Why?
| | Heart Rate | 1 | 2016 | 730 | 0.110 |
Why?
| | China | 4 | 2011 | 173 | 0.110 |
Why?
| | Heart Diseases | 1 | 2015 | 340 | 0.110 |
Why?
| | Varicocele | 1 | 2011 | 10 | 0.100 |
Why?
| | Placenta Diseases | 1 | 2011 | 14 | 0.100 |
Why?
| | Tissue Banks | 1 | 2011 | 19 | 0.100 |
Why?
| | Receptors, Somatomedin | 1 | 2011 | 3 | 0.100 |
Why?
| | Receptors, Glucagon | 1 | 2011 | 23 | 0.100 |
Why?
| | Somatomedins | 1 | 2011 | 27 | 0.100 |
Why?
| | Skin | 1 | 2016 | 658 | 0.100 |
Why?
| | Glucagon | 1 | 2011 | 98 | 0.100 |
Why?
| | Receptor, trkA | 1 | 2011 | 20 | 0.100 |
Why?
| | Narcotics | 1 | 2011 | 49 | 0.100 |
Why?
| | Models, Theoretical | 1 | 2015 | 549 | 0.100 |
Why?
| | Pregnancy Complications | 2 | 2015 | 447 | 0.100 |
Why?
| | Siblings | 2 | 2009 | 228 | 0.100 |
Why?
| | Autoantibodies | 1 | 1999 | 1332 | 0.100 |
Why?
| | Actigraphy | 3 | 2017 | 80 | 0.100 |
Why?
| | Pelvic Organ Prolapse | 1 | 2011 | 41 | 0.100 |
Why?
| | CD4 Lymphocyte Count | 3 | 2006 | 260 | 0.100 |
Why?
| | Gene Expression Regulation | 2 | 2011 | 2433 | 0.100 |
Why?
| | Algorithms | 3 | 2011 | 1520 | 0.100 |
Why?
| | Glucose | 2 | 2007 | 939 | 0.100 |
Why?
| | Protease Inhibitors | 1 | 2011 | 101 | 0.100 |
Why?
| | Skin Physiological Phenomena | 1 | 2010 | 28 | 0.100 |
Why?
| | Sperm Injections, Intracytoplasmic | 1 | 2010 | 8 | 0.090 |
Why?
| | Japan | 3 | 2011 | 97 | 0.090 |
Why?
| | Superovulation | 3 | 2012 | 8 | 0.090 |
Why?
| | Fetal Diseases | 1 | 2011 | 148 | 0.090 |
Why?
| | Pediatric Obesity | 1 | 2017 | 512 | 0.090 |
Why?
| | Decision Trees | 1 | 2010 | 83 | 0.090 |
Why?
| | Hip Fractures | 1 | 2011 | 77 | 0.090 |
Why?
| | Environment | 2 | 2003 | 344 | 0.090 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2011 | 360 | 0.090 |
Why?
| | Proteomics | 1 | 2015 | 850 | 0.090 |
Why?
| | Career Mobility | 1 | 2010 | 64 | 0.090 |
Why?
| | Minisatellite Repeats | 1 | 2009 | 38 | 0.090 |
Why?
| | Lithium Chloride | 1 | 2009 | 12 | 0.090 |
Why?
| | Blood Glucose | 5 | 2019 | 1937 | 0.090 |
Why?
| | Comprehension | 1 | 2011 | 161 | 0.090 |
Why?
| | Health Promotion | 1 | 2015 | 683 | 0.090 |
Why?
| | Magnetic Resonance Angiography | 1 | 2011 | 209 | 0.090 |
Why?
| | Quality Control | 2 | 2000 | 154 | 0.090 |
Why?
| | Blastocyst | 1 | 2009 | 44 | 0.090 |
Why?
| | Glucocorticoids | 1 | 1993 | 546 | 0.090 |
Why?
| | Memory | 1 | 2011 | 231 | 0.080 |
Why?
| | HIV Seropositivity | 2 | 2011 | 111 | 0.080 |
Why?
| | Chorionic Gonadotropin, beta Subunit, Human | 2 | 1999 | 14 | 0.080 |
Why?
| | Perception | 1 | 2011 | 314 | 0.080 |
Why?
| | Sleep Apnea Syndromes | 1 | 2009 | 80 | 0.080 |
Why?
| | Vaginitis | 1 | 2008 | 2 | 0.080 |
Why?
| | Nuclear Pore | 1 | 2008 | 14 | 0.080 |
Why?
| | Autoimmune Diseases | 2 | 2003 | 397 | 0.080 |
Why?
| | Osteoprotegerin | 1 | 2008 | 23 | 0.080 |
Why?
| | Embryo Implantation | 1 | 2008 | 24 | 0.080 |
Why?
| | Wounds and Injuries | 1 | 2015 | 697 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2008 | 1928 | 0.080 |
Why?
| | Uterine Prolapse | 1 | 2008 | 14 | 0.080 |
Why?
| | Coronary Disease | 2 | 2012 | 355 | 0.080 |
Why?
| | Infant, Low Birth Weight | 2 | 2019 | 125 | 0.080 |
Why?
| | Androstenedione | 2 | 1999 | 10 | 0.080 |
Why?
| | Social Class | 1 | 2009 | 217 | 0.080 |
Why?
| | Analysis of Variance | 4 | 2019 | 1285 | 0.080 |
Why?
| | Anthropometry | 1 | 2008 | 192 | 0.080 |
Why?
| | Self Report | 3 | 2018 | 699 | 0.080 |
Why?
| | Skin Absorption | 1 | 2007 | 12 | 0.070 |
Why?
| | Neoplasms | 2 | 1999 | 2153 | 0.070 |
Why?
| | Data Collection | 1 | 2010 | 649 | 0.070 |
Why?
| | Hypoglycemia | 1 | 2011 | 401 | 0.070 |
Why?
| | Cultural Characteristics | 1 | 2007 | 59 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2010 | 342 | 0.070 |
Why?
| | Combined Modality Therapy | 5 | 2021 | 1162 | 0.070 |
Why?
| | Tissue Distribution | 1 | 2007 | 332 | 0.070 |
Why?
| | Receptors, Steroid | 1 | 2007 | 54 | 0.070 |
Why?
| | Research Design | 2 | 2011 | 960 | 0.070 |
Why?
| | Tissue Donors | 1 | 2009 | 334 | 0.070 |
Why?
| | Patient Satisfaction | 2 | 2021 | 609 | 0.070 |
Why?
| | Asparaginase | 3 | 2001 | 28 | 0.070 |
Why?
| | Administration, Topical | 1 | 2007 | 141 | 0.070 |
Why?
| | Relaxin | 2 | 1998 | 15 | 0.070 |
Why?
| | Proteins | 3 | 1989 | 936 | 0.070 |
Why?
| | Nerve Tissue Proteins | 2 | 2011 | 547 | 0.070 |
Why?
| | Lipid Metabolism | 1 | 2009 | 473 | 0.070 |
Why?
| | Age Distribution | 2 | 2004 | 357 | 0.070 |
Why?
| | Gonadal Hormones | 1 | 2005 | 6 | 0.070 |
Why?
| | Spouses | 1 | 2007 | 88 | 0.070 |
Why?
| | Phosphorylation | 2 | 2021 | 1617 | 0.070 |
Why?
| | Preoptic Area | 1 | 2005 | 6 | 0.070 |
Why?
| | Anorexia Nervosa | 1 | 2006 | 74 | 0.070 |
Why?
| | Inhibin-beta Subunits | 1 | 2005 | 5 | 0.070 |
Why?
| | Arthritis, Rheumatoid | 1 | 2014 | 990 | 0.070 |
Why?
| | Maternal Age | 2 | 2022 | 121 | 0.070 |
Why?
| | Population Surveillance | 1 | 2008 | 413 | 0.070 |
Why?
| | Libido | 1 | 2005 | 23 | 0.070 |
Why?
| | Internet | 2 | 2015 | 600 | 0.060 |
Why?
| | Health Services Misuse | 1 | 2005 | 36 | 0.060 |
Why?
| | Phenotype | 3 | 2018 | 2916 | 0.060 |
Why?
| | Interleukin-1 | 1 | 2009 | 979 | 0.060 |
Why?
| | Nuclear Proteins | 3 | 2022 | 591 | 0.060 |
Why?
| | Blastomeres | 1 | 2004 | 12 | 0.060 |
Why?
| | Endoplasmic Reticulum | 1 | 2007 | 240 | 0.060 |
Why?
| | Absorptiometry, Photon | 3 | 2015 | 226 | 0.060 |
Why?
| | Psychiatric Status Rating Scales | 2 | 2017 | 489 | 0.060 |
Why?
| | Vulnerable Populations | 1 | 2005 | 142 | 0.060 |
Why?
| | Lymphoma, Large B-Cell, Diffuse | 1 | 2005 | 94 | 0.060 |
Why?
| | Infusions, Intravenous | 3 | 1994 | 379 | 0.060 |
Why?
| | Sex Characteristics | 3 | 2019 | 667 | 0.060 |
Why?
| | Bone Marrow | 1 | 2005 | 250 | 0.060 |
Why?
| | Mass Screening | 1 | 2011 | 1048 | 0.060 |
Why?
| | Proportional Hazards Models | 1 | 2007 | 1123 | 0.060 |
Why?
| | Central Nervous System | 1 | 2005 | 243 | 0.060 |
Why?
| | Mutation | 2 | 2009 | 3426 | 0.060 |
Why?
| | Glutamic Acid | 1 | 2005 | 221 | 0.060 |
Why?
| | Apoptosis | 2 | 2017 | 2453 | 0.060 |
Why?
| | Minority Groups | 1 | 2005 | 236 | 0.060 |
Why?
| | Contraceptives, Oral | 1 | 2003 | 27 | 0.060 |
Why?
| | Elasticity | 2 | 2016 | 192 | 0.060 |
Why?
| | MicroRNAs | 1 | 2009 | 632 | 0.060 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2023 | 108 | 0.060 |
Why?
| | Sugars | 1 | 2023 | 32 | 0.060 |
Why?
| | Melphalan | 2 | 1999 | 29 | 0.050 |
Why?
| | Pituitary Hormones | 1 | 2022 | 16 | 0.050 |
Why?
| | Remission Induction | 4 | 2009 | 246 | 0.050 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 3 | 2011 | 978 | 0.050 |
Why?
| | Follicular Atresia | 1 | 2002 | 4 | 0.050 |
Why?
| | Whole-Body Irradiation | 2 | 1999 | 72 | 0.050 |
Why?
| | alpha-Amylases | 1 | 2022 | 17 | 0.050 |
Why?
| | Thyroid Hormones | 1 | 2022 | 55 | 0.050 |
Why?
| | Snoring | 1 | 2021 | 11 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 1 | 2011 | 2433 | 0.050 |
Why?
| | Receptors, Estrogen | 1 | 2004 | 383 | 0.050 |
Why?
| | Breast | 1 | 2022 | 137 | 0.050 |
Why?
| | Preconception Care | 1 | 2022 | 28 | 0.050 |
Why?
| | Eukaryotic Initiation Factor-2 | 1 | 2021 | 23 | 0.050 |
Why?
| | Computers | 2 | 2000 | 64 | 0.050 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2022 | 88 | 0.050 |
Why?
| | Maternal-Child Nursing | 1 | 2001 | 10 | 0.050 |
Why?
| | Blood Pressure | 3 | 2017 | 1656 | 0.050 |
Why?
| | Prevotella | 1 | 2021 | 12 | 0.050 |
Why?
| | Nursing Methodology Research | 1 | 2001 | 44 | 0.050 |
Why?
| | Grief | 1 | 2001 | 35 | 0.050 |
Why?
| | Open Reading Frames | 1 | 2021 | 117 | 0.050 |
Why?
| | Canada | 1 | 2022 | 338 | 0.050 |
Why?
| | X Chromosome | 1 | 2001 | 47 | 0.050 |
Why?
| | Hypertension | 1 | 2010 | 1198 | 0.050 |
Why?
| | Pulmonary Blastoma | 1 | 2000 | 7 | 0.050 |
Why?
| | Anger | 1 | 2001 | 59 | 0.050 |
Why?
| | Heparin | 1 | 2022 | 230 | 0.050 |
Why?
| | Body Surface Area | 1 | 2020 | 28 | 0.050 |
Why?
| | Pleural Neoplasms | 1 | 2000 | 18 | 0.050 |
Why?
| | Insemination | 1 | 2020 | 1 | 0.050 |
Why?
| | Illinois | 1 | 2020 | 38 | 0.050 |
Why?
| | Gestures | 1 | 2020 | 5 | 0.050 |
Why?
| | Chicago | 1 | 2020 | 45 | 0.050 |
Why?
| | Paper | 1 | 2000 | 9 | 0.050 |
Why?
| | Blood Volume | 1 | 2020 | 56 | 0.050 |
Why?
| | Radiography | 2 | 2014 | 860 | 0.050 |
Why?
| | Reproducibility of Results | 3 | 2018 | 2855 | 0.050 |
Why?
| | Cell Line | 2 | 2021 | 2688 | 0.050 |
Why?
| | Leukemia, Myelomonocytic, Acute | 1 | 1999 | 7 | 0.050 |
Why?
| | Personal Autonomy | 1 | 2000 | 40 | 0.050 |
Why?
| | Thrombin | 1 | 2000 | 133 | 0.050 |
Why?
| | Kaplan-Meier Estimate | 2 | 2014 | 837 | 0.040 |
Why?
| | Observer Variation | 1 | 2000 | 303 | 0.040 |
Why?
| | Ultrasonography, Prenatal | 1 | 2021 | 227 | 0.040 |
Why?
| | Focus Groups | 1 | 2021 | 387 | 0.040 |
Why?
| | Sex Factors | 2 | 2019 | 1764 | 0.040 |
Why?
| | Antineoplastic Agents, Alkylating | 1 | 1999 | 69 | 0.040 |
Why?
| | Sexual Maturation | 1 | 2019 | 49 | 0.040 |
Why?
| | Cell Division | 1 | 2021 | 770 | 0.040 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 393 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2022 | 276 | 0.040 |
Why?
| | Histiocytosis, Non-Langerhans-Cell | 1 | 1999 | 5 | 0.040 |
Why?
| | Chromosome Breakage | 1 | 1999 | 20 | 0.040 |
Why?
| | Gene Deletion | 1 | 2001 | 359 | 0.040 |
Why?
| | Triglycerides | 2 | 2017 | 515 | 0.040 |
Why?
| | Sensitivity and Specificity | 3 | 2008 | 1783 | 0.040 |
Why?
| | Chromosomes, Human, Pair 9 | 1 | 1999 | 42 | 0.040 |
Why?
| | Chromosome Inversion | 1 | 1999 | 15 | 0.040 |
Why?
| | Educational Status | 2 | 2012 | 435 | 0.040 |
Why?
| | Pregnant Women | 1 | 2000 | 132 | 0.040 |
Why?
| | Neurons | 1 | 2007 | 1338 | 0.040 |
Why?
| | Needs Assessment | 1 | 2001 | 324 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2021 | 407 | 0.040 |
Why?
| | Diet | 2 | 2023 | 1143 | 0.040 |
Why?
| | Insurance, Health | 1 | 2001 | 244 | 0.040 |
Why?
| | Italy | 3 | 2009 | 90 | 0.040 |
Why?
| | Hyperthyroidism | 1 | 2018 | 26 | 0.040 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2021 | 508 | 0.040 |
Why?
| | Injections, Intravenous | 2 | 1990 | 209 | 0.040 |
Why?
| | Microinjections | 1 | 1998 | 83 | 0.040 |
Why?
| | Diagnostic Techniques, Obstetrical and Gynecological | 2 | 2008 | 6 | 0.040 |
Why?
| | Glucuronates | 1 | 2017 | 4 | 0.040 |
Why?
| | Organ Size | 2 | 2010 | 460 | 0.040 |
Why?
| | Cardiovascular System | 1 | 2019 | 127 | 0.040 |
Why?
| | Sleep Apnea, Obstructive | 1 | 2021 | 233 | 0.040 |
Why?
| | Conservative Treatment | 1 | 2018 | 30 | 0.040 |
Why?
| | Islets of Langerhans | 1 | 2004 | 739 | 0.040 |
Why?
| | Cholesterol | 1 | 2019 | 375 | 0.040 |
Why?
| | Transaminases | 1 | 2017 | 26 | 0.040 |
Why?
| | Dietary Supplements | 1 | 2021 | 467 | 0.040 |
Why?
| | Thrombosis | 1 | 2000 | 301 | 0.040 |
Why?
| | Receptors, Angiotensin | 1 | 1997 | 10 | 0.040 |
Why?
| | Immunologic Tests | 1 | 1997 | 16 | 0.040 |
Why?
| | Pregnancy Tests | 1 | 2017 | 7 | 0.040 |
Why?
| | Polymorphism, Restriction Fragment Length | 1 | 1997 | 64 | 0.040 |
Why?
| | Disease-Free Survival | 4 | 2001 | 648 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2018 | 2652 | 0.040 |
Why?
| | Vehicle Emissions | 1 | 2017 | 65 | 0.040 |
Why?
| | Mice | 4 | 2021 | 15424 | 0.040 |
Why?
| | Hypertriglyceridemia | 1 | 2017 | 38 | 0.040 |
Why?
| | Biological Assay | 1 | 2017 | 122 | 0.040 |
Why?
| | Qualitative Research | 1 | 2021 | 945 | 0.040 |
Why?
| | Biopsy | 1 | 2000 | 1073 | 0.040 |
Why?
| | Genes | 1 | 1997 | 224 | 0.040 |
Why?
| | Molecular Weight | 3 | 2013 | 339 | 0.040 |
Why?
| | Hepatitis C | 2 | 2011 | 215 | 0.040 |
Why?
| | Transdermal Patch | 1 | 2016 | 14 | 0.040 |
Why?
| | Energy Metabolism | 1 | 2022 | 761 | 0.040 |
Why?
| | Hyperprolactinemia | 1 | 2016 | 4 | 0.040 |
Why?
| | Substance Abuse, Intravenous | 2 | 2008 | 80 | 0.030 |
Why?
| | Alcohol Drinking | 2 | 2012 | 651 | 0.030 |
Why?
| | Goiter | 1 | 1996 | 3 | 0.030 |
Why?
| | Galvanic Skin Response | 1 | 2016 | 28 | 0.030 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2019 | 369 | 0.030 |
Why?
| | Quality of Health Care | 1 | 2001 | 586 | 0.030 |
Why?
| | Hospitals, Pediatric | 1 | 2019 | 504 | 0.030 |
Why?
| | Transcriptome | 1 | 2021 | 752 | 0.030 |
Why?
| | Serologic Tests | 1 | 2015 | 52 | 0.030 |
Why?
| | Catheters, Indwelling | 2 | 1993 | 82 | 0.030 |
Why?
| | Birth Weight | 1 | 2018 | 463 | 0.030 |
Why?
| | Hypothyroidism | 1 | 1996 | 68 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1339 | 0.030 |
Why?
| | Neuroblastoma | 1 | 1996 | 135 | 0.030 |
Why?
| | Statistics, Nonparametric | 2 | 2011 | 399 | 0.030 |
Why?
| | Histiocytosis, Langerhans-Cell | 1 | 1995 | 35 | 0.030 |
Why?
| | Cranial Irradiation | 2 | 2009 | 69 | 0.030 |
Why?
| | Registries | 2 | 2020 | 1806 | 0.030 |
Why?
| | Antibodies, Monoclonal | 2 | 2014 | 1273 | 0.030 |
Why?
| | Genetic Markers | 2 | 2011 | 338 | 0.030 |
Why?
| | Cyclosporine | 1 | 1995 | 173 | 0.030 |
Why?
| | Neovascularization, Physiologic | 1 | 2016 | 181 | 0.030 |
Why?
| | Peptide Fragments | 1 | 1999 | 688 | 0.030 |
Why?
| | Myocardium | 1 | 2020 | 965 | 0.030 |
Why?
| | Vincristine | 3 | 2001 | 99 | 0.030 |
Why?
| | Deafness | 1 | 1996 | 81 | 0.030 |
Why?
| | Certolizumab Pegol | 1 | 2014 | 3 | 0.030 |
Why?
| | Etanercept | 1 | 2014 | 51 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1376 | 0.030 |
Why?
| | Adalimumab | 1 | 2014 | 43 | 0.030 |
Why?
| | Freezing | 1 | 1994 | 86 | 0.030 |
Why?
| | Osmolar Concentration | 1 | 1994 | 181 | 0.030 |
Why?
| | Glycerol | 1 | 1994 | 88 | 0.030 |
Why?
| | Drug Stability | 1 | 1994 | 153 | 0.030 |
Why?
| | Anions | 1 | 2013 | 31 | 0.030 |
Why?
| | Infliximab | 1 | 2014 | 94 | 0.030 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 2014 | 69 | 0.030 |
Why?
| | Air Pollutants | 1 | 2017 | 302 | 0.030 |
Why?
| | Receptors, Tumor Necrosis Factor | 1 | 2014 | 147 | 0.030 |
Why?
| | Medical Records | 1 | 2014 | 160 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2015 | 816 | 0.030 |
Why?
| | Molecular Conformation | 1 | 2013 | 138 | 0.030 |
Why?
| | Electrocardiography | 1 | 2016 | 555 | 0.030 |
Why?
| | Carrier Proteins | 1 | 1997 | 723 | 0.030 |
Why?
| | Anal Canal | 1 | 1993 | 83 | 0.030 |
Why?
| | Menstruation-Inducing Agents | 1 | 2012 | 1 | 0.030 |
Why?
| | Cell Survival | 2 | 2007 | 1044 | 0.030 |
Why?
| | Urinary Tract Infections | 1 | 2014 | 135 | 0.030 |
Why?
| | Rectal Neoplasms | 1 | 1993 | 121 | 0.030 |
Why?
| | Tea | 1 | 2012 | 10 | 0.030 |
Why?
| | Growth Differentiation Factor 9 | 1 | 2011 | 4 | 0.030 |
Why?
| | Coffee | 1 | 2012 | 13 | 0.030 |
Why?
| | Pituitary Gland, Anterior | 1 | 2011 | 45 | 0.030 |
Why?
| | Alcoholic Beverages | 1 | 2012 | 17 | 0.030 |
Why?
| | Cystocele | 1 | 2011 | 1 | 0.030 |
Why?
| | Rectocele | 1 | 2011 | 3 | 0.030 |
Why?
| | Oogenesis | 1 | 2011 | 27 | 0.030 |
Why?
| | Women | 1 | 2012 | 51 | 0.030 |
Why?
| | Placentation | 1 | 2011 | 42 | 0.030 |
Why?
| | Postoperative Complications | 2 | 2001 | 2230 | 0.030 |
Why?
| | Fetal Death | 1 | 2011 | 53 | 0.030 |
Why?
| | Pregnancy Proteins | 1 | 2011 | 38 | 0.030 |
Why?
| | Ulna Fractures | 1 | 2011 | 13 | 0.030 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2011 | 15 | 0.020 |
Why?
| | Nerve Growth Factor | 1 | 2011 | 28 | 0.020 |
Why?
| | Body Height | 1 | 2012 | 186 | 0.020 |
Why?
| | Receptor, trkB | 1 | 2011 | 28 | 0.020 |
Why?
| | Colon | 1 | 1993 | 237 | 0.020 |
Why?
| | Heterozygote | 1 | 2011 | 258 | 0.020 |
Why?
| | Progesterone Congeners | 1 | 2010 | 15 | 0.020 |
Why?
| | Radius Fractures | 1 | 2011 | 50 | 0.020 |
Why?
| | Waist-Hip Ratio | 1 | 2010 | 31 | 0.020 |
Why?
| | Radioimmunoassay | 1 | 2010 | 164 | 0.020 |
Why?
| | Informed Consent | 1 | 2011 | 162 | 0.020 |
Why?
| | Cross Reactions | 1 | 2010 | 116 | 0.020 |
Why?
| | Dominica | 1 | 2010 | 1 | 0.020 |
Why?
| | Brain-Derived Neurotrophic Factor | 1 | 2011 | 117 | 0.020 |
Why?
| | Proinsulin | 1 | 2010 | 48 | 0.020 |
Why?
| | Spinal Fractures | 1 | 2011 | 77 | 0.020 |
Why?
| | Daunorubicin | 2 | 2001 | 23 | 0.020 |
Why?
| | Survival Rate | 2 | 2009 | 1714 | 0.020 |
Why?
| | Risk Reduction Behavior | 1 | 2012 | 198 | 0.020 |
Why?
| | Statistics as Topic | 1 | 2011 | 304 | 0.020 |
Why?
| | Hematology | 1 | 2009 | 12 | 0.020 |
Why?
| | Antineoplastic Agents | 1 | 2001 | 1950 | 0.020 |
Why?
| | Herpes Zoster | 1 | 2014 | 334 | 0.020 |
Why?
| | Colorado | 1 | 2019 | 4175 | 0.020 |
Why?
| | Ambulatory Care | 1 | 1993 | 481 | 0.020 |
Why?
| | Infusion Pumps | 1 | 1989 | 32 | 0.020 |
Why?
| | Pulse Therapy, Drug | 1 | 2009 | 6 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 668 | 0.020 |
Why?
| | Culture Techniques | 1 | 1989 | 81 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2009 | 64 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 1989 | 104 | 0.020 |
Why?
| | Cyclin D1 | 1 | 2009 | 61 | 0.020 |
Why?
| | Polyethylene Glycols | 1 | 2014 | 575 | 0.020 |
Why?
| | Prednisone | 2 | 2001 | 235 | 0.020 |
Why?
| | Glycogen Synthase Kinase 3 | 1 | 2009 | 82 | 0.020 |
Why?
| | Polysomnography | 1 | 2009 | 156 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2009 | 193 | 0.020 |
Why?
| | Safety | 1 | 1990 | 304 | 0.020 |
Why?
| | West Indies | 1 | 2008 | 5 | 0.020 |
Why?
| | Tartrate-Resistant Acid Phosphatase | 1 | 2008 | 3 | 0.020 |
Why?
| | Acid Phosphatase | 1 | 2008 | 18 | 0.020 |
Why?
| | Hyperhidrosis | 1 | 2008 | 5 | 0.020 |
Why?
| | RANK Ligand | 1 | 2008 | 28 | 0.020 |
Why?
| | Menorrhagia | 1 | 2008 | 14 | 0.020 |
Why?
| | Estrogen Antagonists | 1 | 2008 | 39 | 0.020 |
Why?
| | Papio | 1 | 2008 | 92 | 0.020 |
Why?
| | Chronic Disease | 1 | 2014 | 1634 | 0.020 |
Why?
| | Pelvic Floor | 1 | 2008 | 24 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 2 | 2005 | 2431 | 0.020 |
Why?
| | Medical Oncology | 1 | 2009 | 229 | 0.020 |
Why?
| | Collagen Type I | 1 | 2008 | 114 | 0.020 |
Why?
| | Transplantation, Autologous | 2 | 1999 | 190 | 0.020 |
Why?
| | Lung Neoplasms | 1 | 2000 | 2214 | 0.020 |
Why?
| | Alkaline Phosphatase | 1 | 2008 | 157 | 0.020 |
Why?
| | Microscopy, Immunoelectron | 1 | 2007 | 45 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2008 | 409 | 0.020 |
Why?
| | Isoenzymes | 1 | 2008 | 296 | 0.020 |
Why?
| | Antineoplastic Agents, Hormonal | 1 | 2008 | 142 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2010 | 668 | 0.020 |
Why?
| | Transplantation Conditioning | 2 | 1999 | 152 | 0.020 |
Why?
| | Cell Line, Transformed | 1 | 2007 | 133 | 0.020 |
Why?
| | Obesity, Morbid | 1 | 2010 | 197 | 0.020 |
Why?
| | Early Diagnosis | 1 | 2008 | 226 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2014 | 966 | 0.020 |
Why?
| | Burkitt Lymphoma | 2 | 2000 | 53 | 0.020 |
Why?
| | New York | 1 | 2006 | 113 | 0.020 |
Why?
| | Cell Count | 1 | 2007 | 315 | 0.020 |
Why?
| | Polymorphism, Genetic | 2 | 2000 | 638 | 0.020 |
Why?
| | Neuropsychological Tests | 1 | 2011 | 1000 | 0.020 |
Why?
| | Up-Regulation | 1 | 2009 | 861 | 0.020 |
Why?
| | Sleep Disorders, Intrinsic | 1 | 2005 | 1 | 0.020 |
Why?
| | Body Fluids | 1 | 1986 | 62 | 0.020 |
Why?
| | HIV-1 | 1 | 1991 | 773 | 0.020 |
Why?
| | Placenta | 1 | 2011 | 637 | 0.020 |
Why?
| | Microdialysis | 1 | 2005 | 65 | 0.020 |
Why?
| | Communication | 1 | 2011 | 750 | 0.020 |
Why?
| | Mice, Knockout | 1 | 2011 | 2664 | 0.020 |
Why?
| | Stroke | 1 | 2014 | 1043 | 0.020 |
Why?
| | Neoplasm, Residual | 1 | 2005 | 102 | 0.020 |
Why?
| | Urban Population | 1 | 2008 | 409 | 0.020 |
Why?
| | Phosphoproteins | 1 | 2007 | 303 | 0.020 |
Why?
| | Genomics | 1 | 2009 | 661 | 0.020 |
Why?
| | Demography | 1 | 2005 | 273 | 0.020 |
Why?
| | Life Change Events | 1 | 2005 | 131 | 0.020 |
Why?
| | Mutation, Missense | 1 | 2006 | 300 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2005 | 361 | 0.010 |
Why?
| | Lipoproteins, HDL2 | 1 | 2003 | 2 | 0.010 |
Why?
| | Interviews as Topic | 1 | 2005 | 591 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 873 | 0.010 |
Why?
| | Monitoring, Physiologic | 1 | 1985 | 267 | 0.010 |
Why?
| | Kinetics | 1 | 1986 | 1620 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2011 | 4885 | 0.010 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2005 | 402 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2009 | 4042 | 0.010 |
Why?
| | Estrus | 1 | 2001 | 18 | 0.010 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2000 | 12 | 0.010 |
Why?
| | Calcium | 1 | 2007 | 1148 | 0.010 |
Why?
| | Blood Coagulation Tests | 1 | 2000 | 52 | 0.010 |
Why?
| | Injections, Intramuscular | 1 | 2001 | 116 | 0.010 |
Why?
| | Terminology as Topic | 1 | 2001 | 197 | 0.010 |
Why?
| | Random Allocation | 1 | 2001 | 344 | 0.010 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2005 | 1159 | 0.010 |
Why?
| | Immunophenotyping | 1 | 2000 | 275 | 0.010 |
Why?
| | Transplants | 1 | 1999 | 36 | 0.010 |
Why?
| | Consanguinity | 1 | 1999 | 49 | 0.010 |
Why?
| | Mercaptopurine | 1 | 1998 | 15 | 0.010 |
Why?
| | Guidelines as Topic | 1 | 2001 | 261 | 0.010 |
Why?
| | Thioguanine | 1 | 1998 | 20 | 0.010 |
Why?
| | Leucovorin | 1 | 1998 | 42 | 0.010 |
Why?
| | Insulin-Like Growth Factor Binding Protein 3 | 1 | 1998 | 38 | 0.010 |
Why?
| | Cytarabine | 1 | 1998 | 53 | 0.010 |
Why?
| | Pregnancy Trimester, Third | 1 | 1998 | 69 | 0.010 |
Why?
| | Pregnancy Trimester, Second | 1 | 1998 | 70 | 0.010 |
Why?
| | Cyclophosphamide | 1 | 1998 | 221 | 0.010 |
Why?
| | Chromosome Aberrations | 1 | 1998 | 135 | 0.010 |
Why?
| | Genetic Linkage | 1 | 1999 | 312 | 0.010 |
Why?
| | Receptor, Angiotensin, Type 2 | 1 | 1997 | 8 | 0.010 |
Why?
| | Restriction Mapping | 1 | 1997 | 75 | 0.010 |
Why?
| | Doxorubicin | 1 | 1998 | 300 | 0.010 |
Why?
| | Dexamethasone | 1 | 1998 | 314 | 0.010 |
Why?
| | Introns | 1 | 1997 | 230 | 0.010 |
Why?
| | Exons | 1 | 1997 | 305 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 1997 | 375 | 0.010 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 2 | 1987 | 328 | 0.010 |
Why?
| | Cloning, Molecular | 1 | 1997 | 536 | 0.010 |
Why?
| | Risk | 1 | 1998 | 845 | 0.010 |
Why?
| | Syndrome | 1 | 1996 | 343 | 0.010 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 1996 | 136 | 0.010 |
Why?
| | Drug Resistance | 1 | 1995 | 166 | 0.010 |
Why?
| | Recurrence | 1 | 1996 | 969 | 0.010 |
Why?
| | Colostomy | 1 | 1993 | 26 | 0.010 |
Why?
| | Liver Diseases | 1 | 1996 | 282 | 0.010 |
Why?
| | Testis | 1 | 1994 | 144 | 0.010 |
Why?
| | Base Sequence | 1 | 1997 | 2140 | 0.010 |
Why?
| | Anastomosis, Surgical | 1 | 1993 | 146 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 1997 | 2844 | 0.010 |
Why?
| | Lymphoma, AIDS-Related | 1 | 1991 | 13 | 0.010 |
Why?
| | Genetic Predisposition to Disease | 1 | 2000 | 2238 | 0.010 |
Why?
| | Sarcoma, Kaposi | 1 | 1991 | 73 | 0.010 |
Why?
| | Transcription, Genetic | 1 | 1997 | 1323 | 0.010 |
Why?
| | Reoperation | 1 | 1993 | 554 | 0.010 |
Why?
| | Feedback | 1 | 1990 | 152 | 0.010 |
Why?
| | Carcinoma, Hepatocellular | 1 | 1991 | 227 | 0.010 |
Why?
| | Equipment Contamination | 1 | 1989 | 55 | 0.010 |
Why?
| | Forearm | 1 | 1989 | 117 | 0.010 |
Why?
| | Liver Neoplasms | 1 | 1991 | 526 | 0.000 |
Why?
| | Bacterial Infections | 1 | 1989 | 226 | 0.000 |
Why?
| | Organ Culture Techniques | 1 | 1987 | 148 | 0.000 |
Why?
| | Isoelectric Point | 1 | 1986 | 23 | 0.000 |
Why?
| | Hemoglobins | 1 | 1986 | 318 | 0.000 |
Why?
| | Bacteria | 1 | 1989 | 751 | 0.000 |
Why?
|
|
Santoro's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|